Together, these critical roles in the CNS suggest that PGRN has the potential to be an important therapeutic target for the treatment of various neurodegenerative disorders, particularly Alzheimer’s disease (AD). Here, GRN is linked to early-onset autosomal dominant Alzheimer disease.